TRIM59 induces epithelial‑to‑mesenchymal transition and promotes migration and invasion by PI3K/AKT signaling pathway in medulloblastoma

Gao,Ran; Lv,Guoqing; Zhang,Cuicui; Wang,Xiaoli; Chen,Lijing

doi:10.3892/ol.2018.8432

TRIM59 induces epithelial‑to‑mesenchymal transition and promotes migration and invasion by PI3K/AKT signaling pathway in medulloblastoma

Authors:
- Ran Gao
- Guoqing Lv
- Cuicui Zhang
- Xiaoli Wang
- Lijing Chen
View Affiliations

Affiliations: Department of Pediatrics, Jining No. 1 People's Hospital, Jining, Shandong 272001, P.R. China, Department of Children's Health Prevention and Rehabilitation, Affiliated Hospital of Jining Medical University, Jining, Shandong 272001, P.R. China, Intensive Care Unit, Affiliated Hospital of Jining Medical University, Jining, Shandong 272001, P.R. China, Department of Pediatrics, Shandong Provincial Hospital, Jinan, Shandong 250021, P.R. China
Published online on: April 4, 2018 https://doi.org/10.3892/ol.2018.8432
Pages: 8253-8260
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Medulloblastoma is the most common malignant brain tumor in children. Despite remarkable advances over previous decades, the long‑term survival of patients with medulloblastoma remains poor due to the frequent metastatic nature of this malignancy. The aim of the present study was to examine the role of tripartite motif containing 59 (TRIM59) in cell metastasis in medulloblastoma. It was initially demonstrated that TRIM59 expression was significantly increased in clinical medulloblastoma tissues compared with adjacent non‑cancerous tissues and differentially expressed in a series of medulloblastoma cell lines. The knockdown of TRIM59 in D283 cells resulted in epithelial‑to‑mesenchymal transition (EMT), and decreased cell migratory and invasive capacities. By contrast, the overexpression of TRIM59 in Daoy cells was able to inhibit the EMT process and increase migratory and invasive capacities of the cells. Notably, the knockdown of TRIM59 was able to decrease the protein level of matrix metalloproteinase (MMP)‑2 without altering the levels of MMP‑9, and conversely the overexpression of TRIM59 was able to increase the protein level of MMP‑2. Importantly, the downregulation of TRIM59 in D283 cells was able to inhibit the levels of phosphorylated (p)‑AKT (Ser473), glycogen synthase kinase 3 β(GSK3β; Ser9) and phosphoinositide 3‑kinase (PI3K) p85 (Tyr458) without altering the levels of total protein. The data from the present study suggest that TRIM59 induces epithelial‑to‑mesenchymal transition and promotes migration and invasion by PI3K/AKT signaling pathway in medulloblastoma. This data may provide novel insight into tumor metastasis and pave the way for the development of therapeutic strategies for the treatment of medulloblastoma in the clinic.

View Figures

View References

1	Gajjar A, Chintagumpala M, Ashey D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Ong-term results from a prospective, multicentre trial. Lancet Oncol. 7:813–820. 2006. View Article : Google Scholar : PubMed/NCBI
2	Packer RJ: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma. Curr Neurol Neurosci Rep. 7:130–132. 2007.
3	Aref D and Croul S: Medulloblastoma: Recurrence and metastasis. CNS Oncol. 2:377–385. 2013. View Article : Google Scholar : PubMed/NCBI
4	Horten BC and Rubinstein LJ: Primary cerebral neuroblastoma. A clinicopathological study of 35 cases. Brain. 99:735–756. 1976. View Article : Google Scholar : PubMed/NCBI
5	Mazloom A, Zangeneh AH, Teh BS and Paulino AC: Extraneural metastasis of medulloblastoma. J Clin Oncol. 27:20652009.
6	Elabd S, Meroni G and Blattner C: TRIMming p53's anticancer activity. Oncogene. 35:5577–5584. 2016. View Article : Google Scholar : PubMed/NCBI
7	Lazzari E and Meroni G: TRIM32 ubiquitin E3 ligase, one enzyme for several pathologies: From muscular dystrophy to tumours. Int J Biochem Cell Biol. 79:469–477. 2016. View Article : Google Scholar : PubMed/NCBI
8	Hatakeyama S: TRIM proteins and cancer. Nat Rev Cancer. 11:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
9	de Thé H, Lavau C, Marchio A, Chomienne C, Degos L and Dejean A: The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 66:675–684. 1991. View Article : Google Scholar : PubMed/NCBI
10	Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F and Pelicci PG: TRIM proteins in cancer. Adv Exp Med Biol. 770:77–91. 2012. View Article : Google Scholar : PubMed/NCBI
11	Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, Heery D, Gronemeyer H, Chambon P and Losson R: The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 14:2020–2033. 1995.PubMed/NCBI
12	Licchesi JD, Van Neste L, Tiwari VK, Cope L, Lin X, Baylin SB and Herman JG: Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene. 29:5923–5934. 2010. View Article : Google Scholar : PubMed/NCBI
13	Valiyeva F, Jiang F, Elmaadawi A, Moussa M, Yee SP, Raptis L, Izawa JI, Yang BB, Greenberg NM, Wang F and Xuan JW: Characterization of the oncogenic activity of the novel TRIM59 gene in mouse cancer models. Mol Cancer Ther. 10:1229–1240. 2011. View Article : Google Scholar : PubMed/NCBI
14	Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH and Gao WQ: TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53. Gastroenterology. 147:1043–1054. 2014. View Article : Google Scholar : PubMed/NCBI
15	Khatamianfar V, Valiyeva F, Rennie PS, Lu WY, Yang BB, Bauman GS, Moussa M and Xuan JW: TRIM59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis. BMJ Open. 2:pii: e001410. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhan W, Han T, Zhang C, Xie C, Gan M, Deng K, Fu M and Wang JB: TRIM59 promotes the proliferation and migration of non-small cell lung cancer cells by upregulating cell cycle related proteins. PLoS One. 10:e1425962015. View Article : Google Scholar
17	Liang J, Xing D, Li Z, Shen J, Zhao H and Li S: TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma. Mol Med Rep. 13:5200–5206. 2016. View Article : Google Scholar : PubMed/NCBI
18	Aierken G, Seyiti A, Alifu M and Kuerban G: Knockdown of tripartrtite-59 (TRIM59) inhibits cellular proliferation and migration in human cervical cancer cells. Oncol Res. 25:381–388. 2017. View Article : Google Scholar : PubMed/NCBI
19	Lin WY, Wang H, Song X, Zhang SX, Zhou PS, Sun JM and Li JS: Knockdown of tripartite motif 59 (TRIM59) inhibits tumor growth in prostate cancer. Eur Rev Med Pharmacol Sci. 20:4864–4873. 2016.PubMed/NCBI
20	Li LL, Xue AM, Li BX, Shen YW, Li YH, Luo CL, Zhang MC, Jiang JQ, Xu ZD, Xie JH and Zhao ZQ: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI. Breast Cancer Res. 16:R562014. View Article : Google Scholar : PubMed/NCBI
21	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
22	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
23	Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Möller T, Pesonen S, Hemminki A, Hamerlik P, et al: Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 6:e161862011. View Article : Google Scholar : PubMed/NCBI
24	Shenoy AK, Jin Y, Luo H, Tang M, Pampo C, Shao R, Siemann DW, Wu L, Heldermon CD, Law BK, et al: Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. J Clin Invest. 126:4174–4186. 2016. View Article : Google Scholar : PubMed/NCBI
25	Abdullah LN and Chow EK: Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2:32013. View Article : Google Scholar : PubMed/NCBI
26	Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
27	Phiboonchaiyanan PP, Busaranon K, Ninsontia C and Chanvorachote P: Benzophenone-3 increases metastasis potential in lung cancer cells via epithelial to mesenchymal transition. Cell Biol Toxicol. 33:251–261. 2017. View Article : Google Scholar : PubMed/NCBI
28	Hartmann W, Digon-Söntgerath B, Koch A, Waha A, Endl E, Dani I, Denkhaus D, Goodyer CG, Sörensen N, Wiestler OD and Pietsch T: Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res. 12:3019–3027. 2006. View Article : Google Scholar : PubMed/NCBI
29	Baryawno N, Sveinbjörnsson B, Eksborg S, Chen CS, Kogner P and Johnsen JI: Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res. 70:266–276. 2010. View Article : Google Scholar : PubMed/NCBI
30	Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O and Arcaro A: Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res. 14:6761–6769. 2008. View Article : Google Scholar : PubMed/NCBI
31	Ehrhardt M, Craveiro RB, Holst MI, Pietsch T and Dilloo D: The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy. Oncotarget. 6:802–813. 2015. View Article : Google Scholar : PubMed/NCBI
32	Zhang F, Li M, Wu X, Hu Y, Cao Y, Wang X, Xiang S, Li H, Jiang L, Tan Z, et al: 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. Drug Des Devel Ther. 9:3969–3987. 2015.PubMed/NCBI